Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.

@article{Sun2005PopulationPO,
  title={Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects.},
  author={Yuliang Sun and Jianfeng Lu and Amita Joshi and Peter Compton and Paul Hak Jo Kwon and Rene Bruno},
  journal={Journal of clinical pharmacology},
  year={2005},
  volume={45 4},
  pages={
          468-76
        }
}
The population pharmacokinetics of efalizumab was characterized in patients with moderate to severe plaque psoriasis. The study included 1088 subjects who received 1 or 2 mg/kg/wk subcutaneous efalizumab for 12 weeks from a phase I (64 subjects) and 3 phase III studies with day 42 and/or day 84 trough levels (1024 patients). Due to the limitation of the data, a 1-compartment model with first-order absorption and elimination was used to fit the data. The population means for V/F, Ka, and CL/F… CONTINUE READING
BETA

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 21 CITATIONS

Similar Papers

Loading similar papers…